Background
Acute bacterial skin and skin structure infections (ABSSSI) in the United States (US) are among the most common infections treated in the hospital and are associated with substantial economic burden and a length of treatment that often extends beyond the initial hospital stay 1 . With emerging issue with methicillin-resistant Staphylococcus aureus (MRSA) and the pathogen-specific antibiotic resistance patterns, it requires for increasing healthcare resource utilization, both in hospitalizations and intravenous (IV) antibiotic use. An analysis of hospital claims indicated that approximately 74% of ABSSSI hospitalizations involved empiric treatment with MRSA-active antibiotics 2 . Many patients continued treatment post-hospital discharge. Little is known, however, about real-world prescribing patterns in the US. The purpose of this analysis was to characterize current prescribing patterns at hospital discharge in the US.
Results
• Overall, approximately 35% of a national projection of 2.8 million inpatients having diagnosis of cellulitis, abscess/boil/cyst, and wound infection received one of 5 MRSA-active IV antibiotics during their hospital stay in the US.
• Among ABSSSI inpatients who received MRSA-active IV antibiotics during their hospital stay, 75.2% were discharged with a prescription for continued antibiotic therapy (21% on IV discharge antibiotics and 54% on PO). The medication adherence, patient inconvenience to frequently access outpatient parenteral antibiotic therapy (OPAT) services, and health economic burden of OPAT for patients and healthcare system remain an obstacle to overcome.
• New long-acting antibiotics have the potential to reduce the need for continued ambulatory IV and PO therapy after hospital discharge, improve the drug compliance, and control economic burden in the treatment of ABSSSI patients. 
References Methods
• Among a national projection of 2,804,457 inpatients with ABSSSI in 2013, 59.0%, 11.2%, 17.7%, and 12.2% of them had cellulitis, major abscess/boil/cyst, surgical wound infection and traumatic wound infection, respectively (Figure 1 ).
• 89.6% of ABSSSI inpatients received at least one dose of IV antibiotics during hospitalization.
-Almost 35% of ABSSSI inpatients received at least one of 5 MRSA-active IV antibiotics during their hospital stay. Most frequently used MRSA-active IV antibiotics were vancomycin (23.9%) followed by clindamycin (7.0%), daptomycin (1.9%), tigecycline (0.9%), and linezolid (0.6%) (Figure 2 ).
-Tigecycline was more likely to be given to elderly patients with comorbidities such as diabetes, COPD, or heart disease than clindamycin or vancomycin, which were more likely to be given to younger patient without insurance coverage (Table 1) . ABSSSI patients with liver disease were more likely to receive clindamycin than to receive other 4 MRSA-active antibiotics.
-Teaching, large size hospitals were more likely to prescribe once-daily daptomycin than nonteaching, small-to-median size hospitals. 
Disclosures
This study was funded by The Medicines Company.
A retrospective, observational electronic medical record (EMR) database was reviewed and analyzed for ABSSSI patients in the US.
• Overall, the discharge patterns were observed as follow: (Figure 3 ), -24.8% of patients who received MRSA-active IV antibiotics during hospitalization were discharged without any discharge drug order.
-21.0% of patients were discharged with a prescription for IV antibiotics (with or without PO [oral] antibiotics). 13.6% of patients were discharged with a prescription for MRSA-active IV antibiotics: 8.2% vancomycin, 3.3% daptomycin, 1.4% tigecycline, 0.5% clindamycin and 0.2% linezolid respectively. -54.2% of patients were discharged with only a prescription for PO therapy: 14.3% and 5.5% of patients were prescribed clindamycin PO and linezolid PO respectively.
• Of the patients with any antibiotic prescription, the discharge patterns were different across 5 MRSA-active antibiotic groups (Table 2) : -40.5% and 48.4% of inpatients who received daptomycin and tigecycline during hospitalization were discharged onto the same therapy, respectively. -Approximately half of inpatients who received IV clindamycin (47.7%) and IV linezolid (52.5%) during hospitalization were switched their respective oral formulation at discharge. -The majority of vancomycin inpatients were discharged onto PO antibiotics such as cephalexin, TMP-SMZ, clindamycin or linezolid. 13.2% of vancomycin patients were discharged onto continued IV vancomycin. 
Statistical Analysis
Patient demographic and baseline information, admission source, comorbidities, resource utilization (such as emergency room (ER), intensive care unit (ICU) and length of hospital stay), and discharge antibiotic use were summarized by 5 most frequently used MRSA-active, IV antibiotics received during hospital. Those MRSA-active antibiotics included vancomycin IV, clindamycin IV, daptomycin IV, tigecycline IV, and linezolid IV.
The categorical variables were presented as percentage. The continuous variables were presented as mean. No hypothesis testing was performed. All analyses were conducted using AMR PADDS Tool (Decision Resources, Burlington, MA, USA).
Study Population
Patients were eligible for inclusion in the analysis if they were hospitalized between 1 January 2013 and 31 December 2013; were aged ≥18 years; had a diagnosis of deep/extensive cellulitis, major abscess/boil/cyst, or surgical/traumatic wound infection. Two subpopulations were studied as well:
• Confirmed MRSA: ABSSSI inpatients who had MRSA pathogen confirmed through microbiology lab test • ABSSSI receiving MRSA-active antibiotics: ABSSSI inpatients who received at least one dose of either vancomycin IV, clindamycin IV, daptomycin IV, tigecycline IV or linezolid IV during hospital stay.
In the time frame between abstract submission and poster presentation, the AMR database was updated with the most recently available data. Based on AMR practice and policy, only the most recent data is available for access and analysis. This poster has therefore been updated from first half of 2011 data (most recent available at the time of abstract submission) to full-year 2013 data (most recent available at the time of poster presentation). Please contact kate.sulham@themedco.com for more information or a copy of the 2011 data results.
Data Source
This analysis was conducted using the Arlington Medical Resources (AMR) database: The Hospital Antibiotic Market Guide. AMR, a Decision Resources Group Company, produces syndicated and proprietary audits of acute care hospital service utilization. Each year, AMR collects patient records for hospital inpatients, with coverage across Germany, the United Kingdom, Italy, Spain, France, and the US. AMR collects over 55,000 patient records from over 900 hospitals in these countries annually. Data from individual hospitals is aggregated and projected to national volumes. Antibiotic use for all indications and place in treatment pathway are captured in addition to patient demographic information, concomitant medications, and pathogen information (where applicable).
